Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandip Basu

Showing results (331-340 of 520) with videos related to

Pageof 52
Sort By:
Clinical Nuclear Medicine|November 17, 2023
68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma ProstatePriyanka Verma, Aamir Nazar, Sonali Jadhav, et al.
Molecular Imaging and Biology|December 17, 2010
Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disordersSandip Basu, Babak Saboury, Tom Werner, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 19, 2011
PET and PET/CT in the management of thyroid cancerSandip Basu, Muammer Urhan, Joshua Rosenbaum, et al.
Nuclear Medicine Communications|February 6, 2009
Impact of fluorodeoxyglucose PET on the management of esophageal cancerAli Salavati, Sandip Basu, Pedram Heidari, et al.
Clinical Nuclear Medicine|April 7, 2026
Intramedullary Spinal Cord Metastasis (SCM) From Prostate Carcinoma Detected on [68Ga] Ga-PSMA-11 PET/CTMadhava Reddy Mali, Rahul V Parghane, Sandip Basu
European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2026
Multi-tracer PET reveals profound biological uncoupling in metastatic grade 3 pancreatic NET: beyond the Mib1 indexShyam Kumar Ravada, Rahul V Parghane, Sandip Basu
Seminars in Nuclear Medicine|August 10, 2020
Peptide Receptor Radionuclide Therapy of Neuroendocrine TumorsSandip Basu, Rahul V Parghane, Kamaldeep, et al.
Nuclear Medicine Communications|October 12, 2018
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this settingAshwini Kalshetty, Anant Ramaswamy, Vikas Ostwal, et al.
Clinical Nuclear Medicine|November 27, 2025
Rare Site Colonic Metastasis in Renal Cell Carcinoma: Imaging Features on CECT and Multitracer PET-CT Employing 18F-FDG, 68Ga-FAPI-04, and 68Ga-PSMA-11Shivam Gupta, Sunita Sonavane, Subhash Yadav, et al.
Clinical Nuclear Medicine|March 21, 2017
Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATERahul V Parghane, Sanjay Talole, Kumar Prabhash, et al.
Pageof 52

Showing results (331-340 of 520) with videos related to

Sort By:
Pageof 52
Clinical Nuclear Medicine|November 17, 2023
68 Ga-PSMA-11 PET/CT and 64 CuCl 2 PET/CT Help in Identifying Rare Metastatic Site of Penile Shaft in a Patient of Carcinoma ProstatePriyanka Verma, Aamir Nazar, Sonali Jadhav, et al.
Molecular Imaging and Biology|December 17, 2010
Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disordersSandip Basu, Babak Saboury, Tom Werner, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 19, 2011
PET and PET/CT in the management of thyroid cancerSandip Basu, Muammer Urhan, Joshua Rosenbaum, et al.
Nuclear Medicine Communications|February 6, 2009
Impact of fluorodeoxyglucose PET on the management of esophageal cancerAli Salavati, Sandip Basu, Pedram Heidari, et al.
Clinical Nuclear Medicine|April 7, 2026
Intramedullary Spinal Cord Metastasis (SCM) From Prostate Carcinoma Detected on [68Ga] Ga-PSMA-11 PET/CTMadhava Reddy Mali, Rahul V Parghane, Sandip Basu
European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2026
Multi-tracer PET reveals profound biological uncoupling in metastatic grade 3 pancreatic NET: beyond the Mib1 indexShyam Kumar Ravada, Rahul V Parghane, Sandip Basu
Seminars in Nuclear Medicine|August 10, 2020
Peptide Receptor Radionuclide Therapy of Neuroendocrine TumorsSandip Basu, Rahul V Parghane, Kamaldeep, et al.
Nuclear Medicine Communications|October 12, 2018
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this settingAshwini Kalshetty, Anant Ramaswamy, Vikas Ostwal, et al.
Clinical Nuclear Medicine|November 27, 2025
Rare Site Colonic Metastasis in Renal Cell Carcinoma: Imaging Features on CECT and Multitracer PET-CT Employing 18F-FDG, 68Ga-FAPI-04, and 68Ga-PSMA-11Shivam Gupta, Sunita Sonavane, Subhash Yadav, et al.
Clinical Nuclear Medicine|March 21, 2017
Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATERahul V Parghane, Sanjay Talole, Kumar Prabhash, et al.
Pageof 52